A cost-effectiveness analysis of the Chlamydia Monday - A community-based intervention to decrease the prevalence of chlamydia in Sweden

Abstract

Aims: The study was undertaken to assess the cost-effectiveness of the Chlamydia Monday, 2007. This is a community-based intervention aimed at reducing the prevalence of chlamydia by information and increased availability of testing, treatment and contact tracing in Stockholm. The aim was to analyze the cost-effectiveness by estimating costs, savings and effects on health associated with the intervention, and to determine if cost-effectiveness varies between men and women. Methods: A societal perspective was adopted, meaning all significant costs and consequences were taken into consideration, regardless of who experienced them. A cost-effectiveness model was constructed including costs of the intervention, savings due to avoiding potential costs associated with medical sequels of chlamydia infection, and health gains measured as quality adjusted life years (QALY). Sensitivity analyses were done to explore model and result uncertainty. Results: Total costs were calculated to be 66,787.21; total savings to 30,370.14; and total health gains to 9.852324 QALYs (undiscounted figures). The discounted cost per QALY was 8,346.05 (10,810.77/QALY for women and 6,085.35/QALY for men). Sensitivity analyses included changes in effectiveness, variation of prevalence, reduced risk of sequel progression, inclusion of prevented future production loss and shortened duration for chronic conditions. The cost per QALY was consistently less than 50,000, which is often regarded as cost-effective in a Swedish context. Conclusions: The Chlamydia Monday has been demonstrated by this study to be a cost-effective intervention and should be considered a wise use of society’s resources.

Keywords

Chlamydia trachomatis cost cost-effectiveness intervention PID QALY saving screening

Get full access to this article

View all access options for this article.

References

Swedish Institute of Infectious Disease Control [online]. 2007. Available from: http://www.smittskyddsinstitutet.se/statistik/klamydiainfektion (accessed 29 August 2009).

Nusbaum RHM , Wallace RR , Slatt ML , Konrad CE Sexually transmitted infections and increased risk of co-infection with Human Immunodeficiency Virus. J Am Osteopathic Ass 2004;104:527-35.

Drummond MF , Sculpher MJ , Torrance GW , O’Brien BJ , Stoddart GL Methods for the economic evaluation of health care programmes, 3rd edn. Oxford : Oxford University Press; 2005.

Swedish National Institute of Public Health. Health economics for public health sciences - Introduction and debate. Stockholm: Swedish National Institute of Public Health; 2003.

Buhaug H. , Skjeldestad FE , Backe B. , Dalen A. Cost effectiveness of testing for chlamydial infections in asymptomatic women . Med Care 1989;27(8):833-41.

Adams EJ , Turner KME , Edmunds WJ , Roberts TE , Low N. The cost effectiveness of opportunistic Chlamydia screening in England . Sex Transm Inf 2007;83:267-75.

Welte R. , Kretschmar M. , Leidl R. , van den Hoek A. , Jager JC , Postma MJ Cost-effectiveness of screening programs for Chlamydia trachomatis: a population based dynamic approach. Sex Transm Dis 2000 ;27:518-29.

Townshend JRP , Turner HS Analyzing the effectiveness of Chlamydia screening . J Operational Res Soc 2000; 51:812-24.

Hu D. , Hook 3rd EW , Goldie SJ Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Int Med 2004;141:501-13.

10.

Novak DP , Lindholm L. , Jonsson M. , Karlsson RB A Swedish cost-effectiveness analysis of community-based Chlamydia trachomatis PCR testing of postal urine specimens obtained at home. Scand J Public Health 2004; 32:324-32.

11.

Chen MY , Karvelas M. , Sundararajan V. , Hocking JS , Fairley CK Evidence for the effectiveness of a Chlamydia awareness campaign: increased population rates of Chlamydia testing and detection. Int J STD AIDS 2007;18:239-43.

12.

Oh MK , Grimley DM , Merchant JS , Brown PR , Cecil H. , Hook EW Mass media as a population-level intervention tool for Chlamydia trachomatis screening: report of a pilot study. J Adolesc Health 2002;31:40-7.

13.

Andersen B. , stergaard L. , Moller JK , Olesen F. Effectiveness of a mass media campaign to recruit young adults for testing of Chlamydia trachomatis by use of home obtained and mailed samples. Sex Transm Inf 2001;77:416-18.

14.

Gift TL , Blake DR , Gaydos CA , Marrazzo JM The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2008;35(11 suppl): S51-60.

15.

Roberts TE , Robinson S. , Barton P. , Bryan S. , Low N. Screening for Chlamydia trachomatis: a systematic review of economic evaluations and modeling. Sex Transm Inf 2006;82:193-200.

16.

Turner ME , Adams EJ , Gay N. , Ghani AC , Mercer C. , Edmunds WJ Developing a realistic sexual network model of Chlamydia transmission in Britain. Theoretical Biology and Medical Modelling 2006;3:3.

17.

Swedish Dental and Pharmaceutical Benefits Agency. Pharmaceutical Benefits Boards general guidelines for economic evaluations LFNAR 2003:2 [online]. 2009. Available from: http://www.tlv.se/Upload/Lagar_och_foreskrifter/LAG-lfnar-2003-2.pdf (accessed 10 December 2009).

18.

The Swedish Association of Health Professionals [online]. 2008. Tillgänglig. http://www.vardforbundet.se/templates/VFArticlePage4.aspx?id=18457 (accessed 10 August 2009).

19.

Swedish National Tax Board [online]. 2008. Available from: http://www.skatteverket.se/fordigsomar/arbetsgivareinfotxt/socialavgifter.4.18e1b10334ebe8bc80005862.html (accessed 5 August 2009).

20.

Stockholm Unit of Infectious Disease Control [online]. 2006. Medverkan 2005 Available from: http://webbhotell.sll.se/Global/Smittskyddsenheten/Dokument/Diverse/medverkan2005.pdf (accessed 5 August 2009).

21.

Swedish Pharmaceutical Benefits Board [online]. 2008 Available from: http://www.lfn.se/LFNTemplates/ProductMedSearch.aspx?id=385 (accessed 21 August 2009).

22.

Statistics Sweden [online]. 2006. Available from: http://www.scb.se/templates/pressinfo____178714.asp (accessed 5 August 2009).

23.

Howell MR , Gaydos JC , McKee Jr KT , Quinn TC , Gaydos CA Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. Sex Transm Dis 1999;26:519-26.

24.

van Valkengoed Irene GM , Postma Maarten J. , Morré Servaas A. , van den Brule Adriaan JC , Meijer CJ , et al. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Inf 2001;77:276-82.

25.

Randolph AG , Washington AE Screening for Chlamydia trachomatis in adolescent males: a cost-based decision analysis. Am J Public Health 1990;80:545-50.

26.

Blake DR , Gaudos CA , Quinn TC Cost-effectiveness of screening adolescent males for Chlamydia on admission to detention. Sex Transm Dis 2004 ;31(2):85-95.

27.

Appendix 2: Chlamydia. In: Stratton KR , Durch JS , Lawrence RS , editors. Vaccines for the 21st century: a tool for decision making. Washington, DC: National Academy Press; 2000. pp. 149-58.

28.

Feeny D. The Health Utilities Index: a tool for assessing health benefits. Patient-Reported Outcome Newsletter 2005;34:2-6.

29.

Carré H. , Boman J. , Österlund A. , Gärdén B. , Nylander-Lundqvist E. Improved contact tracing for Chlamydia trachomatis with experienced tracers, tracing for one year back in time and interviewing by phone in remote areas . Sex Transm Inf 2008;84:239-42.

30.

Swedish National Board of Health and Welfare. Guidelines for Cardiac Care, 2008. Appendix 2. 2008. Available from: http://www.socialstyrelsen.se/NR/rdonlyres/ED85322A-C017-473BBF36-D6337EB166A1/10018/20081027_bilaga_991.pdf (accessed 15 August 2009).

31.

Duncan B. , Hart G. Sexuality and health: the hidden costs of screening for Chlamydia trachomatis. BMJ 1999 ;318:931-3.

32.

Ajzen I. , Brown TC , Carvajal F. Explaining the discrepancy between intentions and actions: the case of hypothetical bias in contingent valuation. Pers Soc Psychol Bull 2004;30:1108.

33.

Folland S. , Goodman AC , Stano M. The economics of health and health care, 3rd edn. New Jersey: Prentice Hall ; 1993.

34.

Janssen R. Time prices and the demand for GP services . Soc Sci Med 1992;34:725-33.

35.

Wedig, GJ Health status and the demand for health: results on price elasticities. J Health Economics 1988;7:151-63.

36.

Idahl A. , Boman J. , Kumlin U. , Olofsson JI Demonstration of Chlamydia trachomatis lgG antibodies in the male partner of the infertile couple is correlated with a reduced likelihood of achieving pregnancy. Human Reprod 2004;19:1121-6.

37.

Martius J. , Krohn MA , Hillier SL , Stamm WE , Holmes KK , Eschenbach DA Relationships of vaginal Lactobacillus species, cervical Chlamydia trachomatis, and bacterial vaginosis to preterm birth. Obstet Gynecol 1988;71:89-95.